Clinical Trials Browser

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04964934 2026-04-21

SERENA-6

Phase 3 Active not recruiting

315 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT04862663 2026-04-20

CAPItello-292

Phase 3 Recruiting

895 enrolled

Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT06930859 2026-04-20

ELEGANCE

Recruiting

2,766 enrolled

Breast

Breast Neoplasms

NCT07405801 2026-04-20

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT06726148 2026-04-17

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

280 enrolled

Breast

Breast Neoplasms

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

920 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07400523 2026-04-17

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Phase 3 Recruiting

446 enrolled

Breast

Breast Neoplasms

NCT07085767 2026-04-16

OPERA-02

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT05664893 2026-04-15

CALHYS

Phase 1/2 Withdrawn

Breast

HER2 Negative Breast Cancer Not Immediately Operated

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

57 enrolled

Breast

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

Phase 3 Recruiting

500 enrolled

Breast

Advanced Breast Cancer

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Available

Breast

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07164976 2026-04-13

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

86 enrolled

Breast

Breast Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

1,978 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

200 enrolled

Breast

Locoregional Recurrence

NCT06188520 2026-04-08

CYCAD-1

Phase 1/2 Recruiting

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

134 enrolled

Breast

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

300 enrolled

Breast

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

255 enrolled

Breast

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 3 FDA

Breast

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Completed

2,424 enrolled

Breast

Breast Neoplasms

NCT06830720 2026-04-01

CAROLEEN

Recruiting

3,250 enrolled

Breast

Breast Neoplasms

NCT06905301 2026-04-01

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Phase 3 Not yet recruiting

1,056 enrolled

Breast

HR+/HER2- Breast Cancer

Clinical Trials

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

SERENA-6

CAPItello-292

ELEGANCE

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

OPERA-02

CALHYS

FAIM

Study of INCB123667 in Subjects With Advanced Solid Tumors

Adjuvant WIDER

EvoPAR-BR01

Managed Access Programs for LEE011, Ribociclib

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

RaPhLRR

CYCAD-1

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Roll-over Study to Allow Continued Access to Ribociclib

SIE-3

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

NATALEE

PROSPERITY

CAROLEEN

IMPULSE

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease